Longeveron Inc (LGVN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.71-3.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LGVN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 176.3% |
| Our one-year growth estimate | diamond | 82.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 94.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
LGVN — officer change
Dated 2026-11-05
Director — Ursula Ungaro: A director resigned immediately due to personal health issues, which is a genuine departure but not necessarily negative given the stated reason.
Why it matters: The company has said it is seeking partners, but the supplied updates name no signed deal. A deal could fund work on its programs.
Supportive ifThe company announces a signed deal. It names laromestrocel and a partner, with funding or other support.
Worry ifThe company reports no signed partner. Instead, it delays or stops a laromestrocel program because support is lacking.
Why it matters: At June 30, cash was $10.1 million, and the company said it could fund costs into Q4. Its plans depend on new funding or lower costs.
Worry ifThe November 3 update says cash or new funding can cover operations past Q4 2026.
Less concerning ifThe company reports cash below $10 million with no new funding, or says its runway ends before year-end 2026.
Why it matters: The trial missed its main goal, but a secondary heart-event measure was significant. FDA feedback can clarify whether the program can move forward.
Watch forThe company reports an FDA meeting and a clear next step for HLHS, such as a new trial plan.
Also watch forFDA feedback says the results do not support a next study, or the company reports no meeting or path forward.
Why it matters: The company said it plans a Phase 2 PDCM trial in 2027. A start would add a clinical program while HLHS faces an uncertain path.
Supportive ifThe company announces that the PDCM Phase 2 trial has opened or enrolled its first patient in 2027.
Worry ifThe company delays the planned 2027 trial start or says it has paused PDCM development.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$333 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $816 loss on $10,000 · 8.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,802 loss on $10,000 · 88.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The talk may add detail on the significant MACE result. It can also show how the study limits affect that result.
Watch forAt the November 8 AHA talk, presenters report 1 MACE in the treatment group and 8 in standard care. They report p=0.043 and say the analysis was planned in advance.
Also watch forThe talk reports a different MACE result or no significant result. Or it says the group difference may not be reliable.